JPWO2020157362A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020157362A5 JPWO2020157362A5 JP2021532911A JP2021532911A JPWO2020157362A5 JP WO2020157362 A5 JPWO2020157362 A5 JP WO2020157362A5 JP 2021532911 A JP2021532911 A JP 2021532911A JP 2021532911 A JP2021532911 A JP 2021532911A JP WO2020157362 A5 JPWO2020157362 A5 JP WO2020157362A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- formula
- administered
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024158993A JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382061.0 | 2019-01-30 | ||
| EP19382061 | 2019-01-30 | ||
| US201962913259P | 2019-10-10 | 2019-10-10 | |
| US62/913,259 | 2019-10-10 | ||
| PCT/ES2020/070070 WO2020157362A1 (en) | 2019-01-30 | 2020-01-30 | Inositol phosphate compounds for use in increasing tissular perfusion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158993A Division JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022521119A JP2022521119A (ja) | 2022-04-06 |
| JPWO2020157362A5 true JPWO2020157362A5 (enExample) | 2022-09-14 |
Family
ID=69770927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532911A Pending JP2022521119A (ja) | 2019-01-30 | 2020-01-30 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
| JP2024158993A Pending JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158993A Pending JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220000889A1 (enExample) |
| EP (1) | EP3917535A1 (enExample) |
| JP (2) | JP2022521119A (enExample) |
| KR (1) | KR20210148078A (enExample) |
| CN (1) | CN113365636A (enExample) |
| AU (1) | AU2020213713B2 (enExample) |
| BR (1) | BR112021014897A2 (enExample) |
| CA (1) | CA3130735A1 (enExample) |
| IL (1) | IL285084A (enExample) |
| MX (1) | MX2021008966A (enExample) |
| WO (1) | WO2020157362A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023551660A (ja) * | 2020-11-20 | 2023-12-12 | ヴィフォール （インターナショナル） アーゲー | 石灰化関連腎臓病の治療をするためのイノシトールヘキサキスリン酸アナログ |
| WO2024047037A1 (en) | 2022-08-30 | 2024-03-07 | ETH Zürich | Compositions for parenteral sustained release delivery of hydrophilic drugs |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| EP0632720B1 (en) | 1992-03-25 | 1998-11-11 | Depomed Systems, Inc. | Hydroxyethylcellulose-based sustained-release oral drug dosage froms |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| ATE302597T1 (de) | 1997-06-06 | 2005-09-15 | Depomed Inc | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| AU6912500A (en) * | 1999-08-25 | 2001-03-19 | Gmp Companies, Inc. | Enhanced oxygen delivery in mammals, methods and reagents related thereto |
| WO2001024830A2 (en) * | 1999-10-05 | 2001-04-12 | Theramed, Inc. | Incorporation of chemical substances into cells |
| JP2004510687A (ja) | 1999-11-02 | 2004-04-08 | ディポメド，インコーポレイティド | 胃への薬剤投与の強化のための供給モードの薬理学的誘導 |
| MXPA02007254A (es) | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| WO2002010177A1 (en) * | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Ammonium salts of inositol hexaphosphate and uses thereof |
| WO2002009723A2 (en) * | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| JP3678144B2 (ja) | 2000-12-22 | 2005-08-03 | ウシオ電機株式会社 | フィルム回路基板の周辺露光装置 |
| KR20040020056A (ko) | 2001-05-29 | 2004-03-06 | 디포메드 디벨롭먼트 리미티드 | 위식도 역류 질환 및 야간 위산분비의 치료 방법 |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| US7413751B2 (en) | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| ES2232302B1 (es) | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
| ES2288126B2 (es) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
| ES2332636B1 (es) | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| WO2013045107A1 (en) | 2011-09-29 | 2013-04-04 | Eth Zurich | Pharmaceutical compounds for use in the therapy of clostridium difficile infection |
| EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
| ES2495666B1 (es) * | 2013-03-15 | 2015-08-10 | Laboratoris Sanifit, S.L. | Uso de derivados con enlaces c-o-p en pacientes con fallo renal |
| JP6893037B2 (ja) | 2015-12-11 | 2021-06-23 | エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ | Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート |
| CN108367080B (zh) * | 2015-12-11 | 2021-10-08 | 苏黎世联邦理工学院 | 用于病理性结晶的肌醇衍生物 |
-
2020
- 2020-01-30 KR KR1020217023799A patent/KR20210148078A/ko not_active Ceased
- 2020-01-30 EP EP20709635.5A patent/EP3917535A1/en active Pending
- 2020-01-30 CA CA3130735A patent/CA3130735A1/en active Pending
- 2020-01-30 BR BR112021014897-3A patent/BR112021014897A2/pt unknown
- 2020-01-30 MX MX2021008966A patent/MX2021008966A/es unknown
- 2020-01-30 CN CN202080010978.XA patent/CN113365636A/zh active Pending
- 2020-01-30 AU AU2020213713A patent/AU2020213713B2/en active Active
- 2020-01-30 WO PCT/ES2020/070070 patent/WO2020157362A1/en not_active Ceased
- 2020-01-30 JP JP2021532911A patent/JP2022521119A/ja active Pending
-
2021
- 2021-07-20 US US17/381,052 patent/US20220000889A1/en not_active Abandoned
- 2021-07-22 IL IL285084A patent/IL285084A/en unknown
-
2023
- 2023-04-11 US US18/298,811 patent/US20230248749A1/en not_active Abandoned
-
2024
- 2024-09-13 JP JP2024158993A patent/JP2024175025A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020189864A5 (enExample) | ||
| JP2012503661A5 (enExample) | ||
| JP2010514797A5 (enExample) | ||
| JP2021102643A5 (enExample) | ||
| US20080319038A1 (en) | Preventative or therapeutic agent for acute renal failure | |
| JP2020517736A (ja) | 腎臓損傷の治療及び予防 | |
| JPWO2021050956A5 (enExample) | ||
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| JPWO2020157362A5 (enExample) | ||
| US3868451A (en) | Adenosine-5{40 -esters in treating angina pectoris | |
| JPH1036365A5 (enExample) | ||
| JP2005503323A5 (enExample) | ||
| RU2021125195A (ru) | Соединения инозитолфосфата для применения для увеличения тканевой перфузии | |
| JPWO2021094331A5 (enExample) | ||
| JPS63104960A (ja) | α−［（フェニルメトキシ）メチル］ピリジンアルカノール誘導体 | |
| US4963577A (en) | Use of the thiazole derivative tiprotimod for the preparation of an agent for the therapy of virus infections | |
| JP4078397B2 (ja) | 下痢の予防及び治療剤 | |
| JPWO2023052363A5 (enExample) | ||
| CN1354666A (zh) | 低毒的抗炎抗渗出药物组合物 | |
| EP0717625B1 (en) | A method of treating liver disease and like indications with vasodilating agents | |
| RU2259827C2 (ru) | Лечение или предупреждение гипотензии и шока | |
| JPWO2022162206A5 (enExample) | ||
| CN1019545B (zh) | 制备用于治疗心律不齐的含有喹啉衍生物的组合物的方法 | |
| RU2002133099A (ru) | Применение талипорфина или его производных при лечении заболеваний сердца и получение этих соединений | |
| RU2025113948A (ru) | Бензальдегидные соединения с прямым дестабилизирующим действием на полимеры для лечения серповидно-клеточной болезни |